Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
Autor: | Pavlovsky, Astrid, Altuve, Juan Ignacio Garcia, Cerutti, Amalia, Fiad, Lorena, Kurgansky, Nicolás, Warley, Fernando, Negri Aranguren, Florencia |
---|---|
Zdroj: | In Hematology, Transfusion and Cell Therapy July 2024 |
Databáze: | ScienceDirect |
Externí odkaz: |